Z

Zyversa Therapeutics Inc
NASDAQ:ZVSA

Watchlist Manager
Zyversa Therapeutics Inc
NASDAQ:ZVSA
Watchlist
Price: 1.26 USD -3.08% Market Closed
Market Cap: 1.3m USD
Have any thoughts about
Zyversa Therapeutics Inc?
Write Note

Intrinsic Value

ZVSA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ZVSA stock under the Base Case scenario is 3.05 USD. Compared to the current market price of 1.26 USD, Zyversa Therapeutics Inc is Undervalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZVSA Intrinsic Value
3.05 USD
Undervaluation 59%
Intrinsic Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Backtest
Zyversa Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZVSA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZVSA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Zyversa Therapeutics Inc

Provide an overview of the primary business activities
of Zyversa Therapeutics Inc.

What unique competitive advantages
does Zyversa Therapeutics Inc hold over its rivals?

What risks and challenges
does Zyversa Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zyversa Therapeutics Inc.

Provide P/S
for Zyversa Therapeutics Inc.

Provide P/E
for Zyversa Therapeutics Inc.

Provide P/OCF
for Zyversa Therapeutics Inc.

Provide P/FCFE
for Zyversa Therapeutics Inc.

Provide P/B
for Zyversa Therapeutics Inc.

Provide EV/S
for Zyversa Therapeutics Inc.

Provide EV/GP
for Zyversa Therapeutics Inc.

Provide EV/EBITDA
for Zyversa Therapeutics Inc.

Provide EV/EBIT
for Zyversa Therapeutics Inc.

Provide EV/OCF
for Zyversa Therapeutics Inc.

Provide EV/FCFF
for Zyversa Therapeutics Inc.

Provide EV/IC
for Zyversa Therapeutics Inc.

Show me price targets
for Zyversa Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Zyversa Therapeutics Inc?

How accurate were the past Revenue estimates
for Zyversa Therapeutics Inc?

What are the Net Income projections
for Zyversa Therapeutics Inc?

How accurate were the past Net Income estimates
for Zyversa Therapeutics Inc?

What are the EPS projections
for Zyversa Therapeutics Inc?

How accurate were the past EPS estimates
for Zyversa Therapeutics Inc?

What are the EBIT projections
for Zyversa Therapeutics Inc?

How accurate were the past EBIT estimates
for Zyversa Therapeutics Inc?

Compare the revenue forecasts
for Zyversa Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zyversa Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zyversa Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zyversa Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Zyversa Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zyversa Therapeutics Inc with its peers.

Analyze the financial leverage
of Zyversa Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Zyversa Therapeutics Inc.

Provide ROE
for Zyversa Therapeutics Inc.

Provide ROA
for Zyversa Therapeutics Inc.

Provide ROIC
for Zyversa Therapeutics Inc.

Provide ROCE
for Zyversa Therapeutics Inc.

Provide Gross Margin
for Zyversa Therapeutics Inc.

Provide Operating Margin
for Zyversa Therapeutics Inc.

Provide Net Margin
for Zyversa Therapeutics Inc.

Provide FCF Margin
for Zyversa Therapeutics Inc.

Show all solvency ratios
for Zyversa Therapeutics Inc.

Provide D/E Ratio
for Zyversa Therapeutics Inc.

Provide D/A Ratio
for Zyversa Therapeutics Inc.

Provide Interest Coverage Ratio
for Zyversa Therapeutics Inc.

Provide Altman Z-Score Ratio
for Zyversa Therapeutics Inc.

Provide Quick Ratio
for Zyversa Therapeutics Inc.

Provide Current Ratio
for Zyversa Therapeutics Inc.

Provide Cash Ratio
for Zyversa Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Zyversa Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Zyversa Therapeutics Inc?

What is the current Free Cash Flow
of Zyversa Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zyversa Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zyversa Therapeutics Inc

Current Assets 641.4k
Cash & Short-Term Investments 119.5k
Other Current Assets 521.9k
Non-Current Assets 18.8m
PP&E 1.7k
Intangibles 18.6m
Other Non-Current Assets 178.5k
Current Liabilities 10m
Accounts Payable 8.3m
Accrued Liabilities 1.7m
Non-Current Liabilities 854.6k
Other Non-Current Liabilities 854.6k
Efficiency

Earnings Waterfall
Zyversa Therapeutics Inc

Revenue
0 USD
Operating Expenses
-22.4m USD
Operating Income
-22.4m USD
Other Expenses
554k USD
Net Income
-21.9m USD

Free Cash Flow Analysis
Zyversa Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZVSA Profitability Score
Profitability Due Diligence

Zyversa Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
38/100
Profitability
Score

Zyversa Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

ZVSA Solvency Score
Solvency Due Diligence

Zyversa Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
42/100
Solvency
Score

Zyversa Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZVSA Price Targets Summary
Zyversa Therapeutics Inc

There are no price targets for ZVSA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZVSA?

Click here to dive deeper.

Dividends

Zyversa Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZVSA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Zyversa Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.3m USD

Dividend Yield

0%

Description

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. The firm is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. The firm's development pipeline also includes anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its phase 2a renal product candidate, VAR 200, which mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease.

Contact

FLORIDA
Weston
2200 N. Commerce Parkway, Suite 208
+17542311688
www.zyversa.com

IPO

2021-12-21

Employees

-

Officers

Co-Founder, Chairman, CEO & President
Mr. Stephen C. Glover
CFO & Secretary
Mr. Peter Wolfe
Chief Commercial Officer
Ms. Karen A. Cashmere
Senior Vice President of Corporate Development
Ms. Melda Uzbil O'connell
Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board
Dr. Pablo A. Guzman FACC, M.D.

See Also

Discover More
What is the Intrinsic Value of one ZVSA stock?

The intrinsic value of one ZVSA stock under the Base Case scenario is 3.05 USD.

Is ZVSA stock undervalued or overvalued?

Compared to the current market price of 1.26 USD, Zyversa Therapeutics Inc is Undervalued by 59%.

Back to Top